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accounting for 21.2% and 16.2% of total AED consumption (DDD 
163.7 and 125.2, respectively). In the same year, oxcarbazepine and 
lamotrigine were the most used new AEDs (10.91% and 10.79% of 
total; DDD 84.1 and 83.2, respectively), while gabapentin and pre-
gabalin exhibited the higher incidence of use. The main indication of 
use was epileptic disorders for older AEDs and neuropathic pain for 
newer AEDs. A high number of patients treated with older AEDs, in 
particular carbamazepine, phenobarbital, and valproic acid, received 
coprescription at clinically relevant interaction risk. Among newer 
AEDs, lamotrigine showed a high annual rate of possible interaction.
Conclusion: Significant differences were shown in the prescribing 
pattern of newer and older medications: older AEDs were mainly 
used in the treatment of epileptic disorders, while newer compounds 
were also preferred for conditions other than epilepsy, in particular 
neuropathic pain. The fall in the use of newer AEDs during 2007 
agreed with revised reimbursement criteria for gabapentin and pre-
gabalin. The coprescription should be evaluated with caution and 
avoided if possible. Drugs at risk of interactions should be replaced 
with others having same indication of use.
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Introduction: Drug–drug interactions (DDIs) may have severe and 
life-threatening health consequences. To identify DDIs, a cloud-based 
surveillance has been implemented in a network of 12 pharmacies, 
1 general hospital, and 24 general physicians of the ASS2 Health 
District, North East Italy.
Patients (or Materials) and Methods: DDIs were identified through 
a fully automated, closed loop system that records and updates, by 
specifically designed software interfaces loaded on Information and 
Communication Technology (ICT) programs of the network, all the 
drugs taken during therapy cycle/s. Each patient, agreeing to partici-
pate, was linked through her/his tax code to all prescription/OTC 
drugs managed from October 2012 to March 2013, generating a 
personal pharmacologic profile. Data on age, sex, and comorbidity 
were collected in the beginning of the study. DDIs were identified and 
classified according to Mario Negri Institute definition in 3 severity 
groups: low (no suspension or change in therapy required), moderate 
(change in treatment, additional therapy or hospitalization required), 
and high (potentially fatal).
Results: A total of 369 patients (58.3% women) were included. 
About 30% shown 1 comorbidity and 11.8% 2 or more. 
Cardiovascular diseases (22.7%) represented the most frequent 
comorbidity, followed by musculoskeletal pathology (13.6%), dia-
betes (8.6%), cancer (5.1%), and depression (4.8%). The Charlson 
Comorbidity Index was 0 in 65.2%, 1 in 25.7%, 2 in 7.0% and 3 to 
4 in 2.1%. A total of 67 patients (mean age, 72 [12] years; 52.2% 
women) had at least 1 DDI. About 50% (N = 33) had up to 2 DDIs, 
25% from 3 to 7 DDIs and 25% ≥ 8 (from 9–74 DDIs per person). 
A total of 501 DDIs were identified: the severity was low in 35.5%, 
moderate in 59.7% and high in 4.8%. The top 10 drugs involved in 
DDI were: acetylsalicylic acid (ASA), hydrochlorothiazide, ibupro-
fen, diclofenac, digoxin, nebivolol, pantoprazole, ramipril, furosem-
ide, and nimesulide. DDIs occured more frequently with ASA and 
hydrochlorothiazide (6.2%), hydrochlorothiazide and pantoprazole 
(4.6%), ASA and ibuprofen (3.4%), ASA and nebivolol (3.4%), and 
ASA and nitroglycerin (3.2%). About 50% of DDIs involving ASA, 
hydrochlorothiazide, and ibuprofen were of low severity and another 
50% of moderate severity. For diclofenac, low severity DDIs were 
27.6% and 72.4% moderate while for digoxin 75.7% were moder-
ate and 24.3% high.
Conclusion: ICT technologies are useful to timely identify DDIs of 
clinical relevance and the drugs most frequently involved.
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Introduction: Due to its high solubility and low permeability, nado-
lol, a nonselective β -blocker, is categorized as a class III drug in a 
Biopharmaceutics Classification System, and therefore nadolol may 
require active influx transporters to permeate gut wall mucosa during 
intestinal absorption. Members of the organic anion transporting 
polypeptide (OATP) family such as OATP1A2 and OATP2B1 have 
previously been reported to be involved in intestinal absorption of 
several drugs. However, the molecular mechanism of nadolol uptake 
into enterocytes still remains unknown.
Patients (or Materials) and Methods: Human embryonic kidney 
(HEK) 293 cell lines stably expressing OATP1A2 or OATP2B1 were 
used to investigate whether nadolol is a substrate for these trans-
porters using [3H]nadolol. Epigallocatechin 3-gallate (EGCG), a 
flavonoid highly abundant in green tea, was used as an inhibitor of 
OATP1A2- and OATP2B1-mediated transport.
Results: No significant nadolol uptake was observed in 
OATP2B1-expressing cells. In contrast, the uptake of nadolol in 
OATP1A2-expressing cells was significantly greater than that in 
vector-transfected cells. OATP1A2-mediated nadolol uptake was 
saturable with Km and Vmax values of 84.3 (1.0) μ M and 332.8 
(125.5) pmol/min/mg protein, respectively. OATP1A2-mediated 
uptake of nadolol was inhibited in a concentration dependent man-
ner by EGCG with an IC50 value of 37.3 (5.9) μ M.
Conclusion: These data suggest that OATP1A2 is predominantly 
involved in the cellular uptake of nadolol, while the role of OATP2B1 
may be negligible. The inhibition of OATP1A2-mediated nadolol 
uptake might be involved in drug–drug and drug–food interactions 
with this β -blocker.
Disclosure of Interest: None declared.
PP181—eValuaTIoN of The INTeraCTIoN 
BeTweeN MeThoTrexaTe aNd ProToN PuMP 
INhIBITorS uSINg huMaN oaT1 aNd oaT3 
hek TraNSfeCTed CellS
R. Chioukh1*; M.-S. Noel-Hudson1; S. Ribes1; N. Fournier2;  
L. Becquemont3; and C. Verstuyft4
1EA 4123 Barrières physiologiques et réponses thérapeutiques; 
2UMR1154 Lipides Membranaires et Régulation Fonctionnelle 
du Coeur et des Vaisseaux, Université Paris XI Sud, Chatenay-
Malabry; 3Unite de Recherche Clinique (URC); and 4Service de 
Génétique Moléculaire, Pharmacogénétique et Hormonologie, 
Université Paris XI Sud, Assistance Publique Hôpitaux de Paris, 
Hôpital Bicêtre, France
